$DYN News

Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45

RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35

Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate

Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight Rating

Dyne Therapeutics: A Buy, With Caveats, On DMD Progress

Dyne Therapeutics' Biologics License Application For Zeleciment Rostudirsen Got FDA Acceptance For Review To Treat Duchenne Muscular Dystrophy

TD Cowen Initiates Coverage On Dyne Therapeutics with Buy Rating

Dyne Therapeutics Completes Enrollment In Registrational Expansion Cohort Of Phase 1/2 ACHIEVE Trial Of Zeleciment Basivarsen In Individuals With DM1

Dyne Therapeutics Submits Biologics License Application To FDA For Zeleciment Rostudirsen To Duchenne Muscular Dystrophy

Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission

Dyne Therapeutics Initiates Phase 3 FORZETTO Trial Of Zeleciment Rostudirsen In Individuals With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

Evercore ISI Group Maintains Outperform on Dyne Therapeutics, Lowers Price Target to $33

Bernstein Maintains Market Perform on Dyne Therapeutics, Raises Price Target to $24

Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Could Dyne Therapeutics’ (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline?

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

Dyne Therapeutics Targets 2026 “Breakout Year” With DMD BLA Plans and DM1 Milestones at Stifel Conference

Dyne Therapeutics Advances Rare Disease Pipeline With Pivotal Trials And Data